Risk-adapted BEACOPP regimen can reduce the cumulative dose of chemotherapy for standard and high-risk Hodgkin lymphoma with no impairment of outcome - Dann, E J; Bar-Shalom, R; Tamir, A (Blood, 2007)
et al.